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Abstract This paper aims to examine the relationship be-
tween different characteristics of pain and stiffness and the
functional status of patients with newly diagnosed
polymyalgia rheumatica (PMR). Baseline analysis of an in-
ception cohort study was conducted. Patients aged ≥18 years,
with a new diagnosis of PMRwere recruited from 382 English
general practices. Participants were mailed a baseline ques-
tionnaire, including separate pain and stiffness manikins and
numerical rating scales (NRS), a question on their ability to
raise their arms above their head and the modified Health
Assessment Questionnaire (mHAQ) to examine participants’
functional status. Linear regression analysis, reported as re-
gression co-efficients (95% confidence intervals (95% CI)),
was used to assess the association of pain and stiffness with
function, initially unadjusted and then adjusted for age, gen-
der, deprivation status, smoking status, BMI, anxiety and de-
pression. Six hundred fifty two patients responded to the base-
line survey (88.5%). The majority (88.2%) reported no, or
mild impairment in their functional status. Adjusted linear
regression analysis demonstrated that high (NRS ≥8) pain
(0.20 (95% CI 0.10–0.28)) or stiffness (0.18 (0.09–0.26)) rat-
ings, an increasing number of sites of pain (0.18 (0.06–0.29))
or stiffness (0.19 (0.08–0.31)) and shoulder pain (0.18 (0.05–
0.31)), stiffness (0.10 (0.01–0.20)) and difficulty raising arms
above one’s head (0.19 (0.10–0.28)) were all associated with
increased functional impairment. The majority of newly diag-
nosed PMR patients reported no or minimal functional diffi-
culty. However, those who experience severe or widespread
pain or stiffness often have significant functional limitation in
performing their daily activities and may be a subset worthy of
additional focus in primary care.
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Introduction
Polymyalgia rheumatica (PMR) is an inflammatory condition
seen in patients aged over 50 years, with incidence increasing
with age and peaking between 70 and 80 years. PMR is
characterised by bilateral pain and stiffness in the shoulders,
upper arms or pelvic region, with raised inflammatorymarkers
and a rapid response to glucocorticoid treatment (commonly
prednisolone in the UK). It is also often associated with con-
stitutional symptoms such as fatigue, malaise and weight loss
[1, 2].
Pain and stiffness are common in patients with PMR, and
these symptoms are frequently used to denote the ‘classical’
presentation description of bilateral involvement of the shoul-
ders and hips. Pain and stiffness can also be an indirect marker
of functional ability, an outcome measure reported as more
important to some patients than either specific pain or stiffness
symptoms [3]. Functional status is an important indicator of
patient health, both in isolation and with other outcome mea-
sures. This is positively correlated to C reactive protein (CRP)
[4] and is a strong predictor of mortality in both the general
population and for patients with rheumatoid arthritis (RA) [5].
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Limitations in the patients’ ability to conduct activities of daily
living can have significant negative impacts on self-manage-
ment, drug adherence and mental health [6], presenting it as a
potential marker of future adverse health outcomes.
Though pain, stiffness and functional limitations are not
uncommon in patients with PMR, there is limited research
into the relationship between these during the early stages of
PMR. In a sample of patients with PMR from secondary care,
Hutchings et al. found there to be a major reduction in the
functional status of this group, as measured by the Health
Assessment Questionnaire (HAQ) [6]. They showed that
functional status was significantly below the expected norm
for the general population and that pain and stiffness were
most strongly associated with changes in functional status.
However, patients referred to secondary care are likely to rep-
resent the more severe or atypical end of the disease spectrum
compared to patients in primary care [7], where the majority of
patients with PMR are managed after ruling out a differential
diagnosis that would require further intervention of rheuma-
tology [8].
Our aim was to examine the relationship between different
characteristics of pain and stiffness and the functional status of
newly diagnosed patients with PMR, hypothesising that in-
creased pain or stiffness would be associated with a reduced
ability to perform daily activities.
Methods
Study design and population
We examined patient reported baseline data from an inception
cohort study of patients with newly diagnosed PMR in general
practice. The methods of the PMR cohort study have been
described elsewhere [9], but in summary, newly diagnosed
PMR patients were recruited from 382 general practices from
across England between June 2012 and June 2014. Patients
agreeing to be contacted were mailed a postal questionnaire
and consent form, with a reminder pack sent after 3 weeks for
non-responders. Study approval was obtained from the
Staffordshire Local Research Ethics Committee (Ref no: 12/
WM/0021).
Outcome measures
Participants were asked to rate the severity of their pain and
stiffness using two separate 0–10 numerical rating scales
(NRS), with 0 indicating no pain/stiffness and 10 the worst
pain/stiffness imaginable. The anatomical location of pain and
stiffness were elicited using two separate body manikins [9].
Participants were also asked whether they had difficulty rais-
ing their arms above their head, without reference to whether
pain, stiffness or both limited such movement. Patients’
function in undertaking their usual abilities in the past week
(e.g. get in and out of bed) was assessed using the modified
Heath Assessment Questionnaire (mHAQ) [10].
The baseline questionnaire also collected information on
sample characteristics, including age, gender, body mass in-
dex (BMI, calculated from self-reported height and weight)
and neighbourhood level of deprivation was reported using
the indices of multiple deprivation (IMD) [11]. The 7-item
Generalised Anxiety Disorder (GAD) questionnaire [12] and
Patient Health Questionnaire (PHQ-8) [13] were used to as-
sess the presence of anxiety and depression, respectively.
Statistical analysis
Descriptive statistics were used to summarise the characteris-
tics of the study sample. The mean age (standard deviation
(SD)) and gender were reported. Pain and stiffness were
dichotomised at the median (inter-quartile range (IQR)) into
low (NRS score 0–7) and high (NRS score 8–10) severity.
Using manikin data, participants were categorised by quartiles
into the number of painful body sites (0–9, 10–15, 16–22 or
23–44), and patients with bilateral shoulder and/or hip pain
also identified. Through the samemethods, the number of stiff
sites was categorised (0–5, 6–11, 12–19 or 20–44), and par-
ticipants with bilateral hip and/or shoulder stiffness identified
[14]. Patients who responded to being asked whether they
were able to lift their arms above their head could answer
Byes^, Bno^ or Bdo not know .^ mHAQ scores were categorised
as normal (<0.3), mild (≥0.4 to 1.29), moderate (1.3 to 1.79) or
severe (>1.8) functional impairment, based on previously val-
idated criteria [15].
To assess the association between pain, stiffness and
mHAQ scores, we used linear regression analysis. The rela-
tionship between each pain characteristic and functional status
(mHAQ score) was initially examined, followed by each stiff-
ness characteristic and functional status. Associations were
reported as the regression co-efficient of the mean mHAQ
score with 95% CI. Each association was examined through
unadjusted analysis, followed by adjustment for age, gender,
deprivation status, smoking status, BMI, anxiety and
depression.
IMD was categorised into three groups (the 20% least de-
prived, mid-deprived and 20% most deprived). BMI was
categorised into four groups: (i) <24.9 (healthy weight), (ii)
25.0–29.99 (over weight), (iii) 30.0–34.9 (obese) or (iv)
≥35.0 (severely obese). Smoking status was categorised by
those who had never smoked, were ex-smokers or current
smokers. Anxiety was categorised as none (GAD7 score 0–
4), mild (5–9), moderate (10–14) or severe (15–21).
Depression was categorised as none (PHQ8 score 0–4), mild





A total of 739 patients with PMR were invited into the study,
with 652 responding to the baseline survey (adjusted response
rate 88.5%). The mean age of responders was 72.6 years (SD
9.0), the majority were female (62.0%), and a quarter were
obese (25.8%) (Table 1).
The median NRS severity score for both pain and stiffness
was 8 (IQR 7,9). Approximately half of newly diagnosed
PMR patients reported pain (47.1%) in ≥16 body sites or
stiffness (47.1%) in ≥12 sites. Nearly two-thirds of responders
were unable to raise their arms above their head (64.2%).
The mean mHAQ score was 0.57 (SD 0.57), with 269
(42.8%) responders categorised as having normal functioning
with no impairment, 285 (45.4%) had a mild functional defi-
cit, 50 (8.0%) had moderate and 24 (3.8%) had a severe func-
tional deficit. The percentage of responders with a score
denoting moderate or severe clinically defined anxiety was
13.1%, those with moderate or severe depression was 21.8%.
Association between pain and function
In the unadjusted model, the mean mHAQ score was 0.24
(95%CI 0.15–0.34) points higher (indicating poorer function-
ing) in those with a high pain severity (NRS >8) compared to
those with a low pain severity.When linear regression analysis
was adjusted for age, gender, BMI, deprivation status,
smoking status, anxiety and depression, this was attenuated
to 0.20 (0.10 to 0.28) and remained significant (Table 2).
Unadjusted analysis showed an association between pa-
tients with an increased number of pain sites (16–22 pain sites
0.17 (0.04 to 0.29); 23–44 sites (0.27 (0.15 to 0.39)) and
poorer functional status compared to those with 0–9 pain sites.
When adjusted, this was attenuated to 0.13 (0.01 to 0.25) for
16–22 sites and 0.21 (0.06 to 0.29) for 23–44 sites, though
remained significant.
The relationship between bilateral shoulder pain and func-
tion also showed a significant association. In the unadjusted
model, the mean mHAQ score was 0.22 (0.09 to 0.36) points
higher in those with bilateral shoulder pain compared to those
without. When linear regression analysis was adjusted, this
was attenuated, but remained significant (0.18 (0.05 to
0.31)). There was no statistically significant association be-
tween bilateral hip pain and functional status after adjustment.
Association between stiffness and function
In the unadjusted model, the mean mHAQ score was 0.23
(95% CI 0.14 to 0.32) points higher (poorer functioning) in
those with a high stiffness severity (NRS >8) compared to
those with a low stiffness severity. When linear regression
analysis was adjusted, this remained significant 0.18 (0.09 to
0.26). We also found that as the number of stiffness sites
increased, there was an association with poorer function. In
the unadjusted analysis, there was an association between 6
and 11 stiff sites (0.18 (0.06 to 0.30)), 12–19 stiff sites (0.22
(0.09 to 0.34)) and 20–44 stiff sites (0.31 (0.19 to 0.43), which
remained significant after adjustment (6–11 sites 0.14 (0.03 to
0.26); 12–19 stiffness sites 0.17 (0.05 to 0.29) and 20–44
stiffness sites to 0.19 (0.08 to 0.31) (Table 2).
Though there was an unadjusted association between the
presence of either bilateral shoulder stiffness (0.19 (0.09–
0.28)) or bilateral hip stiffness (0.12 (0.03–0.20)) and the
Table 1 PMR cohort characteristics (N = 652)
Characteristic N (%)
Age (mean (SD)) 72.6 (9.0)
Age (year categories)





Gender (% female) 457 (62.0)
Deprivation status
Least deprived (20%) 125 (19.8)
Middle (60%) 389 (61.5)
Most deprived (20%) 119 (18.7)
Body mass index
<25 kg/m2 210 (33.8)
25.0–29.9 kg/m2 251 (40.4)
30.0–34.9 kg/m2 99 (16.0)
≥35 kg/m2 61 (9.8)
mHAQ (mean (SD)) 0.57 (0.57)
mHAQ (severity categories)
Normal (<0.3) 269 (42.8)
Mild impairment (≥0.3 to <1.3) 285 (45.4)
Moderate impairment (≥1.3 to <1.8) 50 (8)
Severe impairment (≥1.8 to 3.0) 24 (3.8)
Anxiety (GAD-7) (n, %)
None (0–4) 397 (65.2)
Mild (5–9) 132 (21.7)
Moderate (10–14) 49 (8.0)
Severe (15–21) 31 (5.1)
Depression (PHQ-8) (n, %)
None (0–4) 318 (52.9)
Mild (5–9) 152 (25.3)
Moderate (10–14) 70 (11.7)
Moderately severe (15–19) 38 (6.3)
Severe (20–24) 23 (3.8)
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functional status of patients with PMR, this was only retained
for bilateral shoulder stiffness after adjustment.
Finally, an association was examined between the PMR
patients’ ability to raise their arms above their head and func-
tional status. Unadjusted analysis showed that those unable to
raise their arms above their head were significantly more like-
ly to have poorer mHAQ scores than those who could raise
their arms above their head (0.28 (0.18–0.38) and this associ-
ation was retained after adjustment (0.19 (0.10 to 0.28)).
Discussion
Our research used baseline data from an inception cohort of
primary care patients with newly diagnosed PMR to better
understand the relationship between pain, stiffness and the
patients’ ability to function in their daily activities. Our results
demonstrate that in the earliest stages of PMR, over half of
patients have some degree of functional limitation. Those
PMR patients with high pain or stiffness severity, a high
Table 2 Association between
characteristics of pain and
stiffness and functional status
mHAQ Score
Regression coefficient (95% confidence interval)
N (%) Unadjusted Adjusted*
General pain and stiffness
Pain rating
Low (0–7) 217 (33.9) 0 0
High (8–10) 423 (66.1) 0.24 (0.15 to 0.34) 0.20 (0.10 to 0.28)
Number of painful sites
0–9 180 (27.6) 0 0
10–15 165 (25.3) 0.38 (−0.08 to 0.16) 0.05 (−0.07 to 0.16)
16–22 144 (22.1) 0.17 (0.04 to 0.29) 0.13 (0.01 to 0.25)
23–44 163 (25.0) 0.27 (0.15 to 0.39) 0.18 (0.06 to 0.29)
Stiffness rating
Low (0–7) 255 (39.7) 0 0
High (8–10) 387 (60.3) 0.23 (0.14 to 0.32) 0.18 (0.09 to 0.26)
Number of stiff sites
0–5 181 (27.8) 0 0
6–11 164 (25.1) 0.18 (0.06 to 0.30) 0.14 (0.03 to 0.26)
12–19 157 (24.1) 0.22 (0.09 to 0.34) 0.17 (0.05 to 0.29)
20–44 150 (23.0) 0.31 (0.19 to 0.43) 0.19 (0.08 to 0.31)
Localised pain and stiffness
Can you raise your arms above your head?
Yes 184 (28.6) 0 0
No 413 (64.2) 0.28 (0.18 to 0.38) 0.19 (0.10 to 0.28)
Do not know 46 (7.2) 0.17 (−0.02 to 0.35) 0.06 (−0.12 to 0.23)
Bilateral shoulder pain
No 83 (12.7) 0 0
Yes 569 (87.3) 0.22 (0.09 to 0.36) 0.18 (0.05 to 0.31)
Bilateral hip pain
No 237 (36.3) 0 0
Yes 415 (63.7) 0.71 (−0.22 to 0.16) 0.80 (−0.01 to 0.17)
Bilateral shoulder stiffness
No 184 (28.2) 0 0
Yes 468 (71.8) 0.19 (0.09 to 0.28) 0.10 (0.01 to 0.20)
Bilateral hip stiffness
No 313 (48.0) 0 0
Yes 339 (52.0) 0.12 (0.03 to 0.20) 0.07 (−0.02 to 0.15)
Bold = significant difference. *Adjusted for age, gender deprivation, BMI, smoking status, anxiety and depression
and current prednisolone dose
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number of painful or stiff body sites and those with limitations
in the shoulders report significantly poorer functional status.
The ability of newly diagnosed PMR patients to conduct
their daily activities has not previously been examined within
a primary care population. However, two prospective cohort
studies recorded baseline mHAQ scores in secondary care
populations of patients with new-onset PMR. Matteson et al.
reported a median (IQR)mHAQ score of 1.1 (0.8, 1.7) in a US
sample (n = 85) [16] and Dasgupta et al. reported a median
mHAQ score of 1.1 in a sample from the UK (n = 125) [17].
Our sample of primary care PMR patients reported a lower
mean score (better function) than these small samples from
secondary care. Though this variation may potentially be a
result of study design and sample differences, we would ex-
pect those patients’with PMR in the secondary care system to
be those with more severe, atypical or long-standing problems
and therefore potentially poorer ability to function in daily
living [7]. However, while these overall scores do differ, when
categorised by severity of functional difficulties, this previous
research and our own all found impairment in function for the
majority of newly diagnosed PMR patients to be Bmild^
(mHAQ score < 1.3).
Our sample of patients with PMR also has improved func-
tional capacity compared to patients with other rheumatic con-
ditions. Pincus et al. (1999) reported mean mHAQ scores for
patients with RA, fibromyalgia, osteoarthritis or vasculitis
from secondary care to be 1.73, 1.64, 1.52 and 1.39, respec-
tively. These scores suggest that patients with prevalent rheu-
matological conditions are experiencing a Bmoderate^ impact
on function, compared to the Bmild^ impact seen within our
sample, even though these samples were generally 20 years
younger than our participants [18]. Therefore, it appears that
patients with newly diagnosed PMR from primary care are
either not experiencing functional problems, or if so, these
typically represent a mild impairment. Those from secondary
care have, on average, a higher mHAQ score, but function
appears less impaired than for those with other rheumatic con-
ditions. Therefore, those patients with newly diagnosed PMR
reporting severe or widespread pain or stiffness in primary
care may represent a subset of patients who might warrant
additional follow-up and support to ensure improvement or
perhaps interventions (i.e. referral to physiotherapy or occu-
pational therapy) to improve function if function remains im-
paired. However, our study demonstrates the wide spectrum
of PMR severity which GPs see. The more severe cases are
not solely seen in secondary care and this poses some diffi-
culty for GPs in selecting those in need of additional support.
This also indicates the collaborative role which should (and
can) happen between GPs and rheumatologists. Such identifi-
cation is not only important for the patient; loss of function
poses a significant cost, both socially and economically. It
forces increased formal and informal health care costs, it in-
creases the likelihood of additional injuries and increased
consultations to GP practices [19]. Future research may con-
sider how best to use the questions GPs already likely ask
PMR patients during consultations to determine which pa-
tients are likely to require help with regard to function. For
example, asking whether a patient can raise their arms above
their head may be a useful, quick and simple marker of overall
functional limitations.
Strengths & limitations
This study is the first inception cohort study in primary care to
examine newly diagnosed PMR patients. Response rates were
excellent and as this data is based on incident PMR patients,
recall bias is minimised. We were also able to recruit a large
sample of patients across a wide geographical area and there-
fore our results are generalisable to PMR patients from across
England who consult in primary care.
Our limitations include the use of routinely collected data,
including the diagnosis of PMR. It is possible that some peo-
ple referred into the study may not have been considered to
have PMR given time or if reviewed by a rheumatologist and
therefore includes the possibility that some of our PMR pa-
tients were later re-diagnosed with a different condition.
However, our provision of information to GPs through the
recruitment template, the balance of our samples’ demo-
graphics, in addition to large proportions with bilateral shoul-
der and/or hip pain and stiffness, adds further confidence of
the accuracy of the PMR diagnosis, rather than alternative
conditions where patients’ experience widespread pain or
stiffness. Furthermore, this sample represents the cross-
section of individuals that GPs diagnose and manage with
PMR in UK primary care.
Conclusion
Our study demonstrates that the majority of patients with
polymyalgia rheumatica experience no, or mild functional
limitations when newly diagnosed in primary care.
However, a significant association does exist between wide-
spread, severe pain and stiffness and functional status. As the
ability to function in daily activities is so important to patients,
primary care is well placed to examine this subset further. At
the point of diagnosis, early specific assessment of function
(for example, a simple question on ability to raise their arms
already being asked by the GP) may be needed to help to
prioritise and assess patients further for more intensive support
and treatment.
Acknowledgements TH is funded by an NIHR Clinical Lectureship in
General Practice. CDM is funded by the National Institute for Health
Research (NIHR) Collaborations for Leadership in Applied Health
Research and Care West Midlands, the NIHR School for Primary Care
Research and a NIHRResearch Professorship in General Practice (NIHR-
RP-2014-04-026). The PMR cohort study was also funded by an Arthritis
Clin Rheumatol
Research UK Clinician Scientist Award to CDM (grant number 19634).
The study sponsors had no role in the study design; in the collection,
analysis, and interpretation of data; in the writing of the report; and in
the decision to submit the paper for publication. The views and opinions
expressed therein are those of the authors and do not necessarily reflect
those of the NIHR (UK). This paper presents independent research which
is part-funded by the CLAHRCWest Midlands. The views expressed are
those of the author(s) and not necessarily those of the NHS, the NIHR or
the Department of Health. We are grateful for the participation of General
Practice teams and their patients. Acknowledgements are given to the
Keele survey, network, administration and management teams who sup-
ported the study.
Compliance with ethical standards
Disclosures None.
Ethical approval All procedures performed in studies involving hu-
man participants were in accordance with the ethical standards of the
Staffordshire Local Research Ethics Committee (Ref no: 12/WM/0021)
and with the 1964 Helsinki declaration and its later amendments or com-
parable ethical standards.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Gonzalez-Gay MA (2004) Giant cell arteritis and polymyalgia
rheumatica: two different but often overlapping conditions. Semin
Arthritis Rheum 33(5):289–293
2. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ,
Miranda-Filloy JA, Gonzalez-Juanatey C, Martin J et al (2009)
Epidemiology of giant cell arteritis and polymyalgia rheumatica.
Arthritis Care & Research 61(10):1454–1461
3. Mackie SL, Hughes R, Walsh M, Day J, Newton M, Pease C et al
(2015) BAn impediment to living life^: why and how should we
measure stiffness in polymyalgia rheumatica? PLoS One 10(5):
e0126758
4. Kalke S, Mukerjee D, Dasgupta B (2000) A study of the health
assessment questionnaire to evaluate functional status in
polymyalgia rheumatica. Rheumatology (Oxford, England) 39(8):
883–885
5. Sokka T, Hakkinen A, Krishnan E, Hannonen P (2004) Similar
prediction of mortality by the health assessment questionnaire in
patients with rheumatoid arthritis and the general population. Ann
Rheum Dis 63(5):494–497
6. Hutchings A, Hollywood J, Lamping DL, Pease CT, Chakravarty
K, Silverman B et al (2007) Clinical outcomes, quality of life, and
diagnostic uncertainty in the first year of polymyalgia rheumatica.
Arthritis Rheum 57(5):803–809
7. Kremers HM, ReinaldaMS, Crowson CS, Zinsmeister AR, Hunder
GG, Gabriel SE (2005) Use of physician services in a population-
based cohort of patients with polymyalgia rheumatica over the
course of their disease. Arthritis Care & Research 53(3):395–403
8. BarracloughK, LiddellWG, du Toit J, Foy C, Dasgupta B, ThomasM
et al (2008) Polymyalgia rheumatica in primary care: a cohort study of
the diagnostic criteria and outcome. Fam Pract 25(5):328–333
9. Muller S, Hider S, Helliwell T, Bailey J, Barraclough K, Cope L et al
(2012) The epidemiology of polymyalgia rheumatica in primary care:
a research protocol. BMC Musculoskelet Disord 13(1):102
10. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP
(1983) Assessment of patient satisfaction in activities of daily living
using a modified Stanford Health Assessment Questionnaire.
Arthritis Rheum 26(11):1346–1353
11. Communities and neighbourhoods (2011) The English indices of
deprivation 2010. https://www.gov.uk/government/statistics/
english-indices-ofdeprivation-2010. Accessed on June 2017
12. Spitzer RL, Kroenke K, Williams JB, Lowe B (2006) A brief mea-
sure for assessing generalized anxiety disorder: the GAD-7. Arch
Intern Med 166(10):1092–1097
13. Kroenke K, Spitzer RL,Williams J (2001) The PHQ-9: validity of a
brief depression severity measure. J Gen InternMed 16(9):606–613
14. Birrell F, Croft P, Cooper C, Hosie G, Macfarlane GJ, Silman A
(2000) Radiographic change is common in new presenters in pri-
mary care with hip pain. PCR Hip Study Group. Rheumatology
(Oxford, England) 39(7):772–775
15. Maska L, Anderson J, Michaud K (2011) Measures of functional
status and quality of life in rheumatoid arthritis: Health Assessment
Questionnaire Disability Index (HAQ), Modified Health
Assessment Questionnaire (MHAQ), Multidimensional Health
Assessment Questionnaire (MDHAQ), Health Assessment
Questionnaire II (HAQ-II), Improved Health Assessment
Questionnaire (Improved HAQ), and Rheumatoid Arthritis
Quality of Life (RAQoL). Arthritis Care & Research 63(Suppl
11):S4–13
16. Matteson EL, Maradit-Kremers H, Cimmino MA, Schmidt WA,
Schirmer M, Salvarani C et al (2012) Patient-reported outcomes
in polymyalgia rheumatica. J Rheumatol 39(4):795–803
17. Dasgupta B, Cimmino MA, Maradit-Kremers H, Schmidt WA,
Schirmer M, Salvarani C et al (2012) 2012 provisional classifica-
tion criteria for polymyalgia rheumatica: a European League
Against Rheumatism/American College of Rheumatology collabo-
rative initiative. Ann Rheum Dis 71(4):484–492
18. Pincus T, Swearingen C,Wolfe F (1999) Toward a multidimension-
al Health Assessment Questionnaire (MDHAQ): assessment of ad-
vanced activities of daily living and psychological status in the
patient-friendly health assessment questionnaire format. Arthritis
Rheum 42(10):2220–2230
19. Lubeck DP (2003) The costs of musculoskeletal disease: health
needs assessment and health economics. Best Pract Res Clin
Rheumatol 17(3):529–539
Clin Rheumatol
